Published in final edited form as:

Int J Clin Rheumatol. 2015 December ; 10(6): 451–459. doi:10.2217/ijr.15.45.

Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis

Alexis Ogdie^{*,1} and Lihi Eder²

¹Perelman School of Medicine, University of Pennsylvania, White Building, Room 5024, 3400 Spruce St, Philadelphia, PA 19104, USA

²Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada

Abstract

Numerous studies have suggested a link between psoriatic arthritis (PsA) and comorbidities, in particular cardiovascular disease and metabolic comorbidities such as diabetes. The co-existence of these comorbidities is likely the result of systemic inflammation. In order to improve the health of patients with PsA and provide optimal care, these comorbidities must be addressed. However, little is known about how to improve metabolic and cardiovascular health in patients with PsA. In this perspective, we describe the research needs in the area of improving cardiovascular disease and metabolic comorbidities among patients with PsA.

Keywords

cardiovascular disease; diabetes; metabolic disease; obesity; psoriatic arthritis; research

PsA is associated with an increased risk for metabolic comorbidities including cardiovascular disease

Several studies have now demonstrated an increased risk for metabolic comorbidities among patients with psoriasis and psoriatic arthritis [1,2]. In particular, patients with PsA have significantly increased risk of developing incident diabetes and major adverse cardiovascular events (the combined endpoint myocardial infarction, stroke and cardiovascular death) [3,4]. The prevalence of hypertension, diabetes, dyslipidemia, obesity, fatty liver disease and metabolic syndrome are increased in patients with PsA compared with controls [5]. Furthermore, in some studies, the prevalence of these disorders is higher in patients with PsA than that among patients with psoriasis without PsA [6]. Numerous studies have now

* Author for correspondence: Tel.: +1 215 615 4375, Fax: +1 215 614 4412, alexis.ogdie@uphs.upenn.edu.

For reprint orders, please contact: reprints@futuremedicine.com

Financial & competing interests disclosure

A Ogdie is supported by NIH K23AR063764. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

reported these associations, but the solution to the problem is less clear. Little is known about how to improve cardiovascular and metabolic comorbidities in patients with PsA and how these comorbidities affect disease outcomes.

Why is it important to improve the cardiovascular & metabolic health of patients with PsA?

Cardiovascular disease and metabolic comorbidities, such as obesity and diabetes, contribute to earlier death, reduced quality of life, increased healthcare costs and more complex disease management. The US Center for Disease Control (CDC) notes that heart disease, stroke, diabetes and obesity 'are among the most common, costly, and preventable of all health problems' [7]. Cardiovascular disease is the most common cause of death in developed nations and the second leading cause of disability-adjusted life years (DALYs; the total number of years lost to illness, disability or premature death) [8]. Diabetes is the strongest risk factor for cardiovascular disease and has a substantial impact on quality of life and functional ability. Despite improvement in cardiovascular risk reduction and declining smoking rates, the overall prevalence of cardiovascular disease in the USA is projected to continue to rise due to increasing the incidence of obesity and diabetes [9]. Both cardiovascular disease and metabolic disorders, such as diabetes, contribute to reduced quality of life [10] and the more comorbidities affecting a patient with PsA, the greater the impact on quality of life [11]. Furthermore, the presence of these comorbidities in patients with psoriatic disease has implications for both providers and patients: selection of therapies is more complicated for rheumatologists, dermatologists and primary care providers and patients have more physician visits and medications to manage [12]. Knowing that patients with PsA are at risk for development of these comorbidities, we have the ability to prevent these negative outcomes, or at the very least, to identify these disorders early in order to improve long-term outcomes for our patients.

Managing metabolic disease: implications for psoriatic arthritis disease control

Recent studies have suggested that metabolic comorbidities have an effect on disease activity and medication effectiveness [13]. It may, therefore, be important to treat the comorbidity in order to improve outcomes related to psoriatic arthritis. DiMinno and colleagues demonstrated that hepatic steatosis, carotid plaques and obesity are negative predictors of achieving and maintaining minimal disease activity (MDA) [14,15]. Further informing this relationship, Eder *et al.* demonstrated a dose-response association between obesity and achieving sustained MDA [16]. DiMinno and colleagues subsequently performed a randomized study in which patients initiating a TNF- α inhibitor after failure of an oral DMARD were either assigned to a 'hypo caloric diet' (<1500 kcal/day) or 'self-managed diet' (in which patients were told to limit the use of oil and to increase vegetables and fish) [17]. Regardless of the assigned diet, patients who lost at least 5% of their initial body weight had a significantly higher rate of achieving MDA (OR: 3.75 for those who lost 5–10% of their body weight and OR 6.67 for those who lost >10% of their body weight). Although the TNF- α blocker dose-to-weight ratio could contribute to improved disease

activity, a subgroup analysis of patients on infliximab (in whom the dose for weight was changed as weight changed) revealed the same effect. The impact of weight loss may thus extend beyond pharmacodynamic properties of these medications. These results support the proinflammatory role of cytokines and adipokines produced by adipose tissue in worsening disease activity [18].

Inflammation & cardiometabolic disease

Despite being seemingly an organ-specific inflammatory disorder, psoriatic disease is associated with systemic inflammation that is not limited to the skin or the joints. Likewise, it is now widely accepted that atherosclerosis, the main cause of cardiovascular diseases, is an inflammatory disorder in which immune mechanisms interact with atherogenic lipid particles to initiate and propagate lesions in the vascular walls [19]. The inflammatory response in atherosclerosis is regulated by both the innate and adaptive immune systems via the action of cytokines. Increased activity of autoreactive Th1 cells and reduced activity of regulatory T cells resulting in a release of proinflammatory cytokines, such as TNF- α and IFN- γ , are shared pathogenic pathways for the development of atherosclerosis, arthritis and psoriasis [20–22]. The effect of Th17 cell and IL-23/IL-17 axis on promotion and propagation of atherosclerosis is less clear [23]. Metabolic abnormalities including obesity and diabetes mellitus are also strongly linked with systemic inflammation. The adipose tissue is considered to be an endocrine organ that produces a variety of proinflammatory cytokines. These cytokines have deleterious effects on multiple organs including the induction of glucose intolerance and proatherogenic lipid profile. Psoriatic patients display abnormalities in the innate and adaptive immune system that result in high serum levels of proinflammatory cytokine that potentially play a role in the accelerated atherogenesis and metabolic abnormalities found in these patients [24,25].

The extent of inflammation, as reflected by the clinical manifestations of psoriatic disease and by soluble biomarkers, correlates with cardiovascular risk. Several observational studies reported a dose-response association between the severity of psoriasis and PsA and the occurrence of cardiovascular events [26–28]. Patients with more severe clinical manifestations of PsA, including elevated number of dactylitic digits and actively inflamed joints are at higher cardiovascular risk. In line with these findings, studies that used surrogate endpoints of atherosclerosis found an association between measures of disease activity and the extent of atherosclerosis. The assessment of functional and morphological features of the vascular wall provides important insights about the complex interaction between inflammation, cardiometabolic risk factors and atherogenesis [29]. Abnormalities in endothelial function caused by exposure to inflammatory mediators or oxidative stress occur in early stages of atherosclerosis. These abnormalities, as measured by flow-mediated endothelial dependent vasodilatation in the brachial artery, were found to be more prevalent in patients with PsA compared with controls and correlated with serum biomarkers of inflammation [30]. Recent advances in imaging studies allow direct visualization and quantification of vascular inflammation using FDG-PET/CT, which is an important component of plaque formation and rupture. Rose *et al.* assess vascular inflammation in 65 patients with psoriatic disease [31]. They found that sacroiliitis was associated with an increased vascular inflammation after adjusting for traditional cardiovascular risk factors and

PsA. Morphological studies of vascular wall abnormalities assess late stages of atherogenesis by estimating the extent of atherosclerotic plaque burden using ultrasound, CT or MRI of medium to large arteries. Eder *et al.* reported that patients with high burden of carotid atherosclerosis tended to have elevated levels of inflammatory markers (measured by ESR, leukocyte count) and active PsA (measured disease activity in PsA [DAPSA] score) during the course of their disease [32]. Interestingly, no association was observed between the duration of psoriatic disease and the extent of atherosclerosis.

Metabolic abnormalities are also linked with the extent of psoriatic disease-related inflammation. The severity of psoriasis and PsA is associated with abnormal levels of serum biomarkers that reflect metabolic abnormalities and predict future cardiovascular morbidity. Psoriasis severity correlates with insulin resistance, abnormal levels of resistin and leptin. PsA is associated with measures of insulin resistance and leptin compared with psoriasis alone [25]. These observations support the notion that cumulative high level of systemic inflammation promotes atherogenesis and metabolic abnormalities in psoriatic disease and raise the question of whether effective suppression of inflammation reduces cardiovascular risk in patients with psoriatic disease.

Strategies for improving cardiovascular disease & metabolic comorbidities in patients with PsA

Improve screening for & management of traditional cardiovascular risk factors

An obvious strategy for improving cardiovascular disease is to identify and then manage traditional cardiovascular risk factors such as obesity, smoking, hypertension and dyslipidemia. While this is a simple statement, embedded within are many complex, unanswered questions.

Improve recognition of cardiometabolic disease—Both physicians and patients must recognize the increased risk for cardiovascular and metabolic disease in PsA. Educational strategies aimed at patients and physicians are needed. Continuing medical education activities for physicians and pamphlets for patients are potential strategies but it is not clear that simply educating either group changes behavior. Studies are needed to identify the gaps in education and how to best deliver the information to physicians and patients. For example, qualitative research efforts to better understand barriers to screening could lead to the development of directed physician materials, medical record reminders and templates, or online teaching modules. Furthermore, improving recognition goes beyond education: patients need to be empowered to act upon knowledge, for example, to ask providers about their individual risk. Similarly, qualitative research may lead to an improved understanding of how we can best empower patients to assist in coordinating their own care. Additionally, utilization of patient action networks and support groups may stimulate patients to ask their health care providers about their cardiovascular risk.

Assess barriers to screening for comorbidities & cardiovascular risk factors—Assessing and deconstructing barriers to screening for cardiovascular risk factors is similarly needed. We know that CVD screening rates could be improved. This may in part be due to

diffusion of responsibility: many feel cardiovascular risk stratification and assessment of comorbidities should fall to the primary care physician. Additionally, many rheumatologists may be out of touch with current screening and management practices for cardiovascular disease. Rheumatology patients are often complicated and visits are packed with assessing disease activity, managing therapy and medication side effects, and dealing with issues that are more pressing for the patient on that particular day. Similarly, dermatology visits are generally short and a visit for psoriasis can be time consuming. Understanding specific barriers and designing interventions with the help of clinical providers and patients is critical to improving screening rates [33].

Development of quality indicators—Another approach to improving screening and management of traditional CVD risk factors is through the use of quality indicators (QI). QIs specify either a minimum requirement or optimum standard of care and may be used for quality improvement, pay for performance or accreditation. Significant debate exists regarding the use of quality indicators, in particular as pay-for-performance measures. However, in the USA, quality indicators are a reality in the era of the Affordable Care Act. An international expert panel recently developed 11 cardiovascular quality indicators for rheumatoid arthritis (Box 1) [34]. While relevant for rheumatologists, the authors emphasized that the responsibility for these quality initiatives is shared among all of the patient's care providers and suggest the use of these quality indicators to improve communication among providers. The investigators plan to validate the use of the QI developed in clinical practice by testing feasibility and implementation. Additional studies are needed to determine whether such QI change care, enhance communication among care teams and improve outcomes.

Box 1

Quality indicators for cardiovascular health in rheumatoid arthritis developed by an international expert panel

- Communication of increased CV risk in RA: the treating rheumatologist should communicate to the primary care physician (PCP), at least once within the last 2 years, that patients with RA have an increased CV risk.
- CV risk assessment: a formal CV risk assessment according to national guidelines should be done at least once in the first 2 years after evaluation by a rheumatologist; AND if low risk, it should be repeated once every 5 years; OR if initial assessment suggests intermediate or high-risk, then treatment of risk factors according to national guidelines should be recommended.
- Smoking status and cessation counseling: smoking and tobacco use status should be documented at least once in the last year, and if they are current smokers or tobacco users they should be counseling to stop smoking
- Screening for hypertension: blood pressure should be measured and documented in the medical record at 80% of clinic visits
- Communication to PCP about a documented high blood pressure: if a patient has a blood pressure measure during a rheumatology clinic visit that is elevated

(systolic blood pressure ≥ 140 and/or diastolic blood pressure ≥ 90), then the rheumatologist should recommend that it be repeated and treatment initiated or adjusted if indicated

- Measurement of a lipid profile: a lipid profile should be done at least once in the first 2 years after evaluation by a rheumatologist. If low risk according to CV risk scores, the lipid profile should be repeated once every 5 years; OR if CV risk assessment suggests intermediate or high risk, then treatment according to national guidelines should be recommended
- Screening for diabetes: diabetes should be screened for as part of a CV risk assessment at least once within the first 2 years of evaluation by a rheumatologist and once every 5 years in low-risk patients or yearly in intermediate-or-high-risk patients. If screening is abnormal, this information should be communicated to the primary care provider for appropriate followup and management, if indicated (more detail is provided in the original publication)
- Exercise: physical activity goals should be discussed with their rheumatologist at least once yearly
- BMI screening and lifestyle counseling: BMI should be documented at least once every year and if the patient is overweight or obese according to national guidelines, they should be counseled to modify their lifestyle
- Minimizing corticosteroid usage: if a patient is taking oral corticosteroids, there should be evidence of intent to taper the corticosteroids or reduce to the lowest possible dose
- Communication about risks/benefits of anti-inflammatories in patients at high risk of CV events: if the patient has established CV disease OR is at intermediate or high CV risk AND is taking a nonsteroidal anti-inflammatory drug (or cyclooxygenase-2 inhibitor), then a discussion about the potential CV risks should be documented

Adapted with permission from [34].

Develop of guidelines for cardiovascular risk stratification in PsA—

Development of guidelines specific to patients with psoriatic disease, or inflammatory disease more broadly, may improve physician recognition of increased cardiovascular risk and screening for CVD and CVD risk factors. The European Union League Against Rheumatism (EULAR) and the Canadian Dermatology-Rheumatology Comorbidity Initiative have both released recommendations for the management of cardiovascular disease and comorbidities respectively in patients with RA, psoriasis and PsA [35,36]. The American Academy of Dermatology also included information about the comorbidities in their guidelines for the treatment of psoriasis and PsA [37]. However, development of such guidelines is difficult given the relative lack of evidence to inform risk stratification among patients with these inflammatory diseases. Several studies have demonstrated that existing

risk stratification tools (e.g., Framingham and SCORE) underestimate the true inflammatory burden in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis [38–42]. Additional studies to determine risk factors and develop clinical prediction models for cardiovascular disease among patients with psoriatic disease are needed [43]. Questions to be answered include whether level of inflammation should be included and, if yes, how inflammatory burden should be measured. This is particularly difficult in psoriatic arthritis as the disease is highly heterogeneous. Furthermore, clinical prediction models would need to be validated and then studies to assess uptake and long term performance would be required. Ultimately, risk stratification tools should change practice and improve intermediate and/or long-term outcomes (e.g., does cardiovascular risk assessment and subsequent management improve the rate of cardiovascular disease in patients with PsA compared with the general population?) As risk stratification methods are developed, examination of the additive benefit of imaging and biomarkers in risk assessment are also needed.

Optimize the management of cardiovascular disease & metabolic comorbidities in PsA

Improve adherence to recommendations for a healthier lifestyle patients with PsA—Once physicians have assessed a patient’s cardiovascular risk profile, several potential interventions now lie ahead: lifestyle changes including diet modification, increased exercise, weight loss and smoking cessation as well as prescribing of medications, whether for their skin and inflammatory arthritis or for hyperlipidemia and hypertension. These interventions may be overwhelming for both the patient and physician. Fitting successful counseling into a short follow-up visit may not be possible. Furthermore, even under the best of circumstances, patient adherence to these interventions may be suboptimal [44,45]. Therefore, improving the cardiovascular and metabolic health of our patients will necessitate the development of targeted interventions that are designed for patients who have skin and joint disease that may limit their functional ability. Studies to address adherence and effectiveness of such interventions in both the short-term and long-term are subsequently needed.

Develop exercise recommendations for improved cardiovascular health & disease activity—Regular exercise can significantly improve cardiovascular risk. Additionally, in rheumatoid arthritis, exercise has the added benefit of decreasing disease activity [46–48]. However, patients with inflammatory arthritis have many barriers to physical activity such as the belief that exercise will hurt their joints, lack of understanding about why physical activity is important for their health, decreased self-efficacy around physical activity, poor environment for exercise, inability to afford gym memberships, lack of insurance coverage for physical therapy or other structured exercise programs, perceived lack of time for physical activity, and lack of intrinsic and extrinsic motivators [49]. The role and benefits of exercise in PsA has been understudied [50]. Further studies are needed to examine the impact of exercise on both cardiovascular/metabolic outcomes and disease activity in PsA. Furthermore, methods for reducing barriers to exercise are similarly needed [51].

Determine appropriate thresholds for lipid lowering therapy initiation—Once metabolic comorbidities are identified, it is similarly important to determine whether management strategies should be the same for patients with PsA as for the general population. While patients with RA generally have altered lipid profiles (thought to be one of the reasons for increased adverse cardiovascular events), there may in fact be a paradoxical relationship between lipids and cardiovascular events in the setting of chronic inflammation, although this is debated [52]. This phenomenon is illustrated in RA patients where lipid levels rise as disease activity declines following initiation of treatment for RA [53]. Less is known about lipid levels and how they change with therapy in PsA [54]. Furthermore, it is unclear whether low density lipoprotein thresholds used for initiation of therapy in the general population should be used for patients with PsA or whether a lower cutoff value is needed. Understanding what role statins play will be important, particularly in a disease where liver abnormalities are common due to the high prevalence of fatty liver disease and the high propensity for the development of diabetes.

Impact of treatment for comorbidities on PsA outcomes—Identifying and managing comorbidities may lead to improvements in quality of life, disease activity and therapy response. In the previously mentioned study by DiMinno *et al.*, weight loss resulted in an improved response to TNF- α inhibitors [17]. Similarly, statins may also have an anti-inflammatory effect and may result in improved mortality [55,56]. Is it also possible that improved control of diabetes or improved fatty liver disease leads to improved disease activity? Can dietary changes or supplements improve both metabolic disease and inflammation? Studies are needed to address these concepts.

Determine the impact of therapy for PsA on comorbidities—The suppression of inflammation is a promising novel approach for the management of cardiovascular risk in the general population and among patients with chronic inflammatory conditions [57]. Two ongoing clinical trials (CIRT and CANTOS) assess the efficacy of methotrexate and IL-1 β blockers in cardiovascular risk reduction among high risk individuals who do not have arthritis or psoriasis [58]. The effect of DMARDs and biologics on cardiovascular outcomes in psoriatic disease has only been assessed in observational studies. A recent meta-analysis found that systemic therapy with DMARDs or TNF- α blockers was associated with reduced risk of developing cardiovascular events (RR 0.75; 95% CI: 0.63, 0.91) [59]. Limited data exist about the effect of the distinct class of DMARDs in psoriatic patients. Chin *et al.* found a protective effect of methotrexate (adjusted RR 0.48; 95% CI: 0.29, 0.81) on cardiovascular risk in patients with psoriasis and PsA using national administrative database from Taiwan [60]. A recent study by Ogdie *et al.* reported a higher cardiovascular risk in PsA patients who were not using nonbiologic DMARDs compared with those who were using these medication (adjusted RR 1.34 vs. 0.93) suggesting a protective effect of DMARDs [3].

More information exists about cardiovascular risk and the use of biologic medications, in particular TNF- α blockers in patients with psoriatic disease. The use of TNF- α blockers was associated with an improved profile of cardiovascular biomarkers such as CRP, homocystein, Apo-A-I, Lp(a) and fibrinogen, however, the levels of Apo-B and triglycerides were increased (Sattar, Crompton *et al.* 2007). In addition, the use of TNF- α blockers was

associated with a lower risk of developing diabetes mellitus in patients with psoriasis and RA (adjusted RR 0.62, 95% 0.42, 0.91) [61,62]. Several large population-based studies found an inverse association between the use of TNF- α blockers and cardiovascular events in psoriatic patients. Armstrong *et al.* reported a reduced risk of MI in psoriasis patients using TNF- α blockers compared with those using only topical treatment (adjusted RR 0.50; 95% CI: 0.32, 0.79) [63]. The use of TNF- α blockers and methotrexate was associated with reduced cardiovascular risk compared with topical medications and phototherapy in patients with psoriasis (RR 0.46; 95% CI: 0.22, 0.98 and 0.56; 95% CI: 0.42, 0.76, respectively) from Denmark. No association was found between treatment with IL-23/12 inhibitors and cardiovascular events [64]. In line with these results, Wu *et al.* reported that the risk of developing cardiovascular events was reduced in psoriasis patients who were using TNF- α blockers compared with those using other systemic therapies or phototherapy (RR 0.50; 95% CI: 0.32, 0.79) [65]. Overall, it appears that TNF- α blockade might have a beneficial effect on cardiovascular risk. However, several limitations related to existing literature should be noted. Firstly, these data are based on observational studies in which there is no randomization of the treatment. Therefore, confounding by indication may affect the results. Additionally, studies that are based on administrative databases do not include information about the severity of the skin or the joint disease which may affect the outcome. In addition, most studies assessed psoriasis patients and only a few performed a subgroup analysis with PsA patients.

Lastly, the information about cardiovascular risk and anti-IL-12/23 inhibitors is limited. Concerns were raised about a potential increase in major cardiovascular events related to the use of anti-IL-12/23 agents in psoriatic patients, which led to the discontinuation of all briakinumab trials. A meta-analysis that assessed cardiovascular risk in clinical trials of the two anti-IL-23/12 inhibitors, ustekinumab and briakinumab, did not find a statistically significant difference in the risk compared with placebo [66]; however, this analysis may have been underpowered. Additional information is needed to determine the cardiovascular safety of this class of drugs. Data about the effect of the newer classes of medications for psoriatic disease, including, phosphodiesterase-4 inhibitor (apremilast) and the IL-17 inhibitors, on cardiovascular risk is scarce. Furthermore, it is currently unclear whether there is a differential effect of various biologic and non-biologic DMARDs on cardiovascular risk profile or whether the mere suppression of inflammation irrespective of the medication used, as in the 'treat to target' approach, improves cardiovascular outcomes. Additionally, the relative impact of the skin and the joint inflammation on cardiovascular risk is unknown and it is unclear whether we should target one more than the other to improve cardiovascular outcome.

Overall, there is not enough information to recommend therapies for psoriatic disease on the basis of their cardiovascular risk. However, it appears that TNF- α blockers offer cardiovascular safety and possibly benefit and may be preferred over other systemic therapies in patients who are at increased cardiovascular risk, although relatively little is known.

Conclusion

Optimal care of the patient with PsA means not only treating the skin and joint disease but also identifying comorbidities and making sure that these comorbidities are appropriately addressed. Epidemiologic studies have provided significant advances in our understanding of comorbidities associated with psoriatic disease over the past 10 years. However, little is known about how to address comorbidities in order to improve outcomes and enhance care. Much work remains in understanding the complex relationship between psoriatic arthritis and cardiometabolic comorbidities.

Future perspective

Over the next 5–10 years, major goals for the field will be improved understanding of: the mechanism for increased metabolic disease in patients with psoriatic disease; the impact of systemic therapy for PsA on metabolic and/or cardiovascular disease; and the best methods for managing CVD and metabolic comorbidities in the setting of systemic inflammatory disorders such as PsA. Now that CVD and metabolic disease are better recognized as part of the disease process, additional studies determining the effects of currently available and newer disease modifying agents are likely to follow. Ideally, clinical trials would investigate whether medications for PsA improve cardiovascular outcomes but the feasibility of such trials may be limited by the relative rarity of CV events and such trials may be unethical due to the need to treat patients with placebo for a prolonged period of time. Studies incorporating validated surrogate endpoints (biomarkers, vascular imaging) may thus be acceptable alternatives. In addition, such studies will need to address whether simply suppressing inflammation is sufficient or whether certain mechanisms or drug classes have directed effects on cardiometabolic disease.

References

Papers of special note have been highlighted as:

• of interest

1. Ogdie A, Schwartzman S, Husni M. Recognizing and managing comorbidities in psoriatic arthritis. *Curr Opin Rheumatol*. 2015; 27(2):118–126. [PubMed: 25603040]
2. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. *JAMA Dermatol*. 2013; 149(10):1173–1179. [PubMed: 23925466]
3. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis*. 2015; 74(2):326–332. [PubMed: 25351522]
4. Dubreuli M, Rho YH, Man A, et al. The risk of diabetes in psoriatic arthritis and rheumatoid arthritis. *Arthritis Rheum*. 2012; 64(S10):S1107.
5. Jamnitski A, Symmons D, Peters MJL, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. *Ann Rheum Dis*. 2013; 72(2):211–216. Excellent review on the prevalence and incidence of cardiovascular and metabolic disorders in PsA. [PubMed: 22532629]
6. Lin YC, Dalal D, Churton S, et al. Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2014; 66(1):97–103. [PubMed: 23983044]

7. Centers for Disease Control and Prevention. Chronic diseases: the leading causes of death and disability in the United States. www.cdc.gov/chronicdisease/overview
8. National Institute of Mental Health. US leading categories of diseases/disorders. 2015. www.nimh.nih.gov/health/statistics/disability/us-leading-categories-of-diseases-disorders.shtml
9. Pandya A, Gaziano T, Weinstein M, Cutler D. More Americans living longer with cardiovascular disease will increase costs while lowering quality of life. *Health Aff (Millwood)*. 2013; 32(10): 1706–1714. [PubMed: 24101059]
10. Djärv T, Wikman A, Lagergren P. Number and burden of cardiovascular diseases in relation to health-related quality of life in a cross-sectional population-based cohort study. *BMJ Open*. 2012; 2(5):e001554.
11. Husted J, Thavaneswaran A, Chandran V, Gladman D. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. *J Rheumatol*. 2013; 40(8):1349–1356. [PubMed: 23772076]
12. Centers for Disease Control and Prevention. Health related quality of life reveals full impact of chronic diseases. 2015.
13. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. *J Rheumatol*. 2014; 41(7):1357–1365. [PubMed: 24931949]
14. DiMinno MN, Peluso R, Iervolino S, et al. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-alpha blockers treatment: a prospective study. *Arthritis Res Ther*. 2012; 14(5):R211. [PubMed: 23036698]
15. DiMinno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2013; 65(1):141–147. [PubMed: 22514189]
16. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. *Ann Rheum Dis*. 2014; 74(5):813–817. [PubMed: 24431392]
17. Di Minno M, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. *Ann Rheum Dis*. 2014; 73(6):1157–1162. First prospective interventional study to examine the effect of weight loss on achievement of minimal disease activity in PsA. [PubMed: 23771989]
18. Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcomes and management. *Rheumatology (Oxford)*. 2013; 52(1):62–67. Excellent review of mechanisms of inflammation in obesity and psoriatic arthritis. [PubMed: 22989426]
19. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005; 352(16):1685–1695. [PubMed: 15843671]
20. Späth F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. *Br J Dermatol*. 2008; 159(Suppl 2):10–17. [PubMed: 18700910]
21. Haraoui B, Liu P, Papp K. Managing cardiovascular risk in patients with chronic inflammatory diseases. *Clin Rheumatol*. 2012; 31(4):585–594. [PubMed: 22246418]
22. Sarwar N, Butterworth A, et al. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet*. 2012; 379(9822):1205–1213. [PubMed: 22421339]
23. Gong F, Liu Z, Liu J, Zhou P, Liu Y, Lu X. The paradoxical role of IL-17 in atherosclerosis. *Cell Immunol*. 2015; 297(1):33–39. [PubMed: 26077826]
24. Siegel D, Devaraj S, Mitra A, Raychaudhuri S, Raychaudhuri S, Jialal I. Inflammation, atherosclerosis, and psoriasis. *Clin Rev Allergy Immunol*. 2013; 44(2):194–204. [PubMed: 22359071]
25. Tam L, Kitas G, González-Gay M. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? *Rheumatology (Oxford)*. 2014; 53(6):1108–1119. [PubMed: 24501245]
26. Gelfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A. Risk of myocardial infarction in patients with psoriasis. *JAMA*. 2006; 296(14):1735–1742. [PubMed: 17032986]

27. Ahlehoff O, Gislasen G, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. *J Intern Med.* 2011; 270(2):147–157. [PubMed: 21114692]
28. Maradit-Kremers H, Icen M, Ernste FC, Dierkhising RA, McEvoy MT. Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study. *J Eur Acad Dermatol Venereol.* 2012; 26(3):336–343. [PubMed: 22339785]
29. Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS, Carroll D, Kitas GD. Vascular function and morphology in rheumatoid arthritis: a systematic review. *Rheumatology (Oxford).* 2011; 50(11): 2125–2139. [PubMed: 21926155]
30. Gonzalez-Juanatey C. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. 2007; 57(2):287–293.
31. Rose S, Dave J, Millo C, Naik H, Siegel E, Mehta N. Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative. *Arthritis Res Ther.* 2014; 16(4):R161. [PubMed: 25078679]
32. Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman D. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. *Ann Rheum Dis.* 2015; 74(10):1830–1835. [PubMed: 24827532]
33. Pearson T, Bazzarre T, Daniels S, et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policymakers from the American Heart Association Expert Panel on Population and Prevention Science. *Circulation.* 2003; 107(4):645–651. [PubMed: 12566381]
34. Barber C, Marshall D, Alvarez N, et al. Development of cardiovascular quality indicators for rheumatoid arthritis: results from an international expert panel using a novel online process. *J Rheumatol.* 2015; 42(9):1548–1555. Reports the development of the quality indicators summarized in Box 1. [PubMed: 26178275]
35. Peters M, Symmons D, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis.* 2010; 69:325–331. EULAR guidelines for the management of cardiovascular risk in patients with RA and PsA. [PubMed: 19773290]
36. Roubille C, Richer V, Starnino T, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. *J Rheumatol.* 2015 Jul; 42(10): 1767–1780. [PubMed: 26178281]
37. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2008; 58(5): 826–850. [PubMed: 18423260]
38. Eder L, Chandran V, Gladman DD, Gladman DD. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. *Ann Rheum Dis.* 2013; 73(11):1990–1996. Demonstrates the inadequacy of the Framingham risk score in determining CV risk in patients with PsA and psoriasis. [PubMed: 23887287]
39. Gómez-Vaquero C, Corrales A, Zacarías A, Rueda-Gotor J, Blanco R. SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. *Arthritis Res Ther.* 2013; 15(4):R91. [PubMed: 23965231]
40. Crowson CS, Matteson EL, Roger VL, Thorneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. *Am J Cardiol.* 2012; 110(3):420–424. [PubMed: 22521305]
41. Gisondi P, Farina S, Giordano M, Girolomoni G. Usefulness of the framingham risk score in patients with chronic psoriasis. *Am J Cardiol.* 2010; 106(12):1754–1757. [PubMed: 21055711]
42. Torres T, Sales R, Vasconcelos C, Martins da Silva B, Selores M. Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. *J Dermatol.* 2013; 40(11):923–926. [PubMed: 24128349]

- 43•. Solomon DH, Greenberg J, Curtis JR, et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. *Arthritis Rheumatol.* 2015; 67(8):1995–2003. Reports the new derivation of a cardiovascular risk score for rheumatoid arthritis. A similar method could be considered in deriving a risk score for psoriatic arthritis. [PubMed: 25989470]
44. Knittle K, De Gucht V, Maes S. Lifestyle- and behaviour-change interventions in musculoskeletal conditions. *Best Pract Res Clin Rheumatol.* 2012; 26(3):293–304. [PubMed: 22867927]
45. Chimenti MS, Triggianese P, Conigliaro P, Santoro M, Lucchetti R, Perricone R. Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity. *Drug Dev Res.* 2014; 75(Suppl 1):S57–S59. [PubMed: 25381979]
46. Lemmey AB, Marcora SM, Chester K, Wilson S, Casanova F, Maddison PJ. Effects of high-intensity resistance training in patients with rheumatoid arthritis: a randomized controlled trial. *Arthritis Rheum.* 2009; 61(12):1726–1734. [PubMed: 19950325]
47. Knittle K, De Gucht V, Hurkmans E, et al. Effect of self-efficacy and physical activity goal achievement on arthritis pain and quality of life in patients with rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2011; 63(11):1613–1619. [PubMed: 21898861]
48. Iversen M, Brawerman M, Iversen C. Recommendations and the state of the evidence for physical activity interventions for adults with rheumatoid arthritis: 2007 to present. *Int J Clin Rheumatol.* 2012; 7(5):489–503. [PubMed: 23538738]
49. Bouma A, van Wilgen P, Dijkstra A. The barrier-belief approach in the counseling of physical activity. *Patient Educ Couns.* 2015; 98(2):129–136. [PubMed: 25455791]
50. O'Dwyer T, O'Shea F, Wilson F. Exercise therapy for spondyloarthritis: a systematic review. *Rheumatol Int.* 2014; 34(7):887–902. [PubMed: 24549404]
51. Teixeira PJ, Carraça EV, Markland D, Silva MN, Ryan RM. Exercise, physical activity, and self-determination theory: a systematic review. *Int J Behav Nutr Phys Act.* 2012; 22(9):78. [PubMed: 22726453]
52. Liao KP, Liu J, Lu B, Solomon DH, Kim SC. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis patients. *Arthritis Rheumatol.* 2015; 67(8):2004–2010. [PubMed: 25917955]
53. McGrath CM, Young SP. Lipid and Metabolic Changes in Rheumatoid Arthritis. *Curr Rheumatol Rep.* 2015; 17(9):534.
54. Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. *Ann Rheum Dis.* 2000; 59(11):904–909. [PubMed: 11053070]
55. Lv S, Liu Y, Zou Z, et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. *Clin Exp Rheumatol.* 2015; 33(1):69–76. [PubMed: 25327393]
- 56•. Schoenfeld SR, Lu L, Rai SK, Seeger JD, Zhang Y, Choi HK. Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. *Ann Rheum Dis.* 2015 Epub ahead of print. Reports improved mortality rates in patients with RA who were taking a statin compared with those not prescribed a statin after propensity score matching.
57. Ridker P. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? *Curr Atheroscler Rep.* 2013; 15(1):295. [PubMed: 23225175]
58. Ridker P. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? *Trans Am Clin Climatol Assoc.* 2013; 124:174–190. [PubMed: 23874021]
59. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Ann Rheum Dis.* 2015; 74(3):480–489. [PubMed: 25561362]
60. Chin Y, Yu H, Li W, et al. Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. *J Eur Acad Dermatol Venereol.* 2013; 27(10):1262–1268. [PubMed: 23004680]

61. Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. *Ann Rheum Dis*. 2010; 69(12):2114–2117. [PubMed: 20584807]
62. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. *Arthritis Rheum*. 2007; 56(3):831–839. [PubMed: 17328057]
63. Armstrong A. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients? *JAMA*. 2013; 309(19):2043–2044. [PubMed: 23677316]
64. Ahlehoff O, Skov L, Gislasen G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. *J Eur Acad Dermatol Venereol*. 2015; 29(6):1128–1134. [PubMed: 25303139]
65. Wu J, Poon K. Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both. *J Drugs Dermatol*. 2014; 13(8):932–934. [PubMed: 25116971]
66. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. *JAMA*. 2011; 306(8):864–871. [PubMed: 21862748]

Executive summary

PsA is associated with an increased risk for metabolic comorbidities including cardiovascular disease

- Systemic inflammation is associated with psoriatic disease likely drives the development of atherosclerosis and insulin resistance. Additional research is needed to better understand the mechanisms.

How can we improve cardiovascular & metabolic outcomes in patients with PsA?

- Improved screening and detection may be achieved through assessing barriers to screening, developing quality indicators, and eventually defining PsA-specific cardiovascular risk stratification tools.
- The management of CVD and metabolic comorbidities can be optimized through improving adherence to healthier lifestyles among patients with PsA, better understanding lipid metabolism in the setting of systemic inflammation, defining thresholds for lipid lowering therapy initiation and understanding the impact of treatment of the comorbidities on PsA outcomes.
- We additionally need to better understand the impact of therapy for PsA on CVD outcomes and metabolic comorbidities.